[go: up one dir, main page]

MX2010001571A - Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. - Google Patents

Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Info

Publication number
MX2010001571A
MX2010001571A MX2010001571A MX2010001571A MX2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A
Authority
MX
Mexico
Prior art keywords
egfr inhibitor
inhibitor treatment
predictive markers
predictive
markers
Prior art date
Application number
MX2010001571A
Other languages
English (en)
Inventor
Verena Lutz
Paul Delmar
Barbara Klughammer
Patricia Mcloughlin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010001571A publication Critical patent/MX2010001571A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona biomarcadores que son predictivos para el beneficio clínico al tratamiento con el inhibidor de EGFR en pacientes con cáncer.
MX2010001571A 2007-08-14 2008-08-07 Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. MX2010001571A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114292 2007-08-14
PCT/EP2008/006513 WO2009021674A1 (en) 2007-08-14 2008-08-07 Predictive markers for egfr inhibitor treatment

Publications (1)

Publication Number Publication Date
MX2010001571A true MX2010001571A (es) 2010-03-15

Family

ID=39884813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001571A MX2010001571A (es) 2007-08-14 2008-08-07 Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Country Status (9)

Country Link
EP (1) EP2188391A1 (es)
JP (1) JP2010535517A (es)
KR (1) KR20100037637A (es)
CN (1) CN101778954A (es)
AU (1) AU2008286407A1 (es)
BR (1) BRPI0815415A2 (es)
CA (1) CA2695485A1 (es)
MX (1) MX2010001571A (es)
WO (1) WO2009021674A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095030A1 (en) * 2009-04-17 2012-04-19 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
CN108732350A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Pla2g6作为指示肝内结节及早期预警肝癌的生物标志物
CN108732351A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Eps8l2作为指示肝内结节及早期预警肝癌的生物标志物
CN108732349A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Lta4h作为指示肝内结节及早期预警肝癌的生物标志物
CN110780072B (zh) * 2019-12-09 2021-08-06 四川大学华西医院 Apoo自身抗体检测试剂在制备肺癌筛查试剂盒中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
WO2001079556A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2004211955B2 (en) * 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
KR101126560B1 (ko) * 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법
US8093011B2 (en) 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors

Also Published As

Publication number Publication date
KR20100037637A (ko) 2010-04-09
WO2009021674A1 (en) 2009-02-19
BRPI0815415A2 (pt) 2015-02-03
CA2695485A1 (en) 2009-02-19
CN101778954A (zh) 2010-07-14
JP2010535517A (ja) 2010-11-25
EP2188391A1 (en) 2010-05-26
AU2008286407A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
EA201171367A1 (ru) Винилиндазолильные соединения
WO2010017515A3 (en) Breast cancer specific markers and methods of use
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2009092108A3 (en) Biomarkers for the diagnosis and treatment of pancreatic cancer
MX2010001571A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
WO2008054598A8 (en) Panel of biomarkers for prediction of fti efficacy
WO2010015538A3 (en) Predictive marker for egfr inhibitor treatment
MX2010001573A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
EP2099458A4 (en) COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR PRESENTATION AND THERAPY
BR112013009143A2 (pt) método in vitro, uso e invenção
MX2010001577A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001582A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001583A (es) Maracdor predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001578A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001579A (es) Maracador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
MX2010001570A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal